Latest Clinical Trials
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... National Cancer Institute (NCI) NA
RECRUITING
(Sep 16, 2026)
PHASE1, PHASE2 Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy University of Arkansas NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Stibium Metallicum Praeparatum D6 Versus Placebo in the Reduction of Paclitaxel-induced Peripheral Neurotoxicity University of Bern NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. Fondazione Italiana Linfomi - ETS NA
RECRUITING
(Sep 1, 2026)
PHASE2 Sequential Therapy in Multiple Myeloma Guided by MRD Assessments University of Alabama at Birmingham NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Celgene NA
RECRUITING
(Sep 1, 2026)
PHASE3 Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure Eastern Cooperative Oncology Group NA
RECRUITING
(Sep 1, 2026)
PHASE2 Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Dana-Farber Cancer Institute NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Innovent Biologics (Suzhou) Co. Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Dana-Farber Cancer Institute NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 20, 2026)
PHASE2 A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
TERMINATED
(Aug 1, 2026)
PHASE2 A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Hackensack Meridian Health NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib Tel-Aviv Sourasky Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Canadian Myeloma Research Group NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Pfizer NA
RECRUITING
(Aug 1, 2026)
PHASE3 Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) Starton Therapeutics, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Pfizer NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma AbbVie NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) St. Jude Children's Research Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Intergroupe Francophone du Myelome NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Janssen Research & Development, LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) GlaxoSmithKline NA
RECRUITING
(Aug 1, 2026)
PHASE2 Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma PrECOG, LLC. NA
RECRUITING
(Aug 1, 2026)
PHASE3 Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Andrew Hantel, MD NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE3 Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Janssen Research & Development, LLC NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis AbbVie NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Weill Medical College of Cornell University NA
COMPLETED
(Jul 1, 2026)
PHASE2 Selinexor and Backbone Treatments of Multiple Myeloma Patients Karyopharm Therapeutics Inc NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara European Myeloma Network B.V. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Wake Forest University Health Sciences NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy University of Michigan Rogel Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute NA
COMPLETED
(Jul 1, 2026)
PHASE2 Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion University of Utah NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Kite, A Gilead Company NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) Masonic Cancer Center, University of Minnesota NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis GlaxoSmithKline NA
RECRUITING
(Jul 1, 2026)
PHASE2 Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis Peking University People's Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis Nexcella Inc. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells The Affiliated People's Hospital of Ningbo University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Natural Killer Cells and Bortezomib to Treat Cancer National Heart, Lung, and Blood Institute (NHLBI) NA
COMPLETED
(Jun 25, 2026)
PHASE1 Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance University Health Network, Toronto NA
COMPLETED
(Jun 1, 2026)
PHASE2 Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PrECOG, LLC. NA
COMPLETED
(Jun 1, 2026)
PHASE1, PHASE2 Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) Haukeland University Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Celgene NA
COMPLETED
(Jun 1, 2026)
PHASE3 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial ECOG-ACRIN Cancer Research Group NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Regeneron Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE1 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide PETHEMA Foundation NA
RECRUITING
(Jun 1, 2026)
PHASE3 Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment SWOG Cancer Research Network NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE2 Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE2 Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Children's Oncology Group NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Massachusetts General Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Regeneron Pharmaceuticals NA
WITHDRAWN
(Jun 1, 2026)
PHASE2, PHASE3 Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer University of Southern California NA
TERMINATED
(May 1, 2026)
PHASE2 Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy University of Arkansas NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia National Cancer Institute (NCI) NA
COMPLETED
(May 1, 2026)
PHASE3 Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Mayo Clinic NA
COMPLETED
(May 1, 2026)
PHASE2 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Janssen Research & Development, LLC NA
COMPLETED
(May 1, 2026)
PHASE3 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Antengene Corporation NA
COMPLETED
(May 1, 2026)
PHASE3 Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Northwell Health NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial University of Southern California NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Tanja Andrea Gruber NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma PETHEMA Foundation NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation UNC Lineberger Comprehensive Cancer Center NA
WITHDRAWN
(May 1, 2026)
PHASE2 All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Universitätsklinikum Hamburg-Eppendorf NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment GlaxoSmithKline NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE2 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma SWOG Cancer Research Network NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors National Cancer Institute (NCI) NA
COMPLETED
(Apr 1, 2026)
PHASE1 Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Memorial Sloan Kettering Cancer Center NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Sanofi NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. Asan Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE2 A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Takeda NA
COMPLETED
(Apr 1, 2026)
PHASE1 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma Henan Cancer Hospital NA
COMPLETED
(Apr 1, 2026)
PHASE2 Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM Jacob Laubach, MD NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia Tanja Andrea Gruber NA
COMPLETED
(Apr 1, 2026)
PHASE1 Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Mayo Clinic NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor Asan Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 GIST Oral Paclitaxel(Liporaxel) Asan Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma GlaxoSmithKline NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years University Hospital, Toulouse NA
COMPLETED
(Mar 1, 2026)
PHASE3 Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT Hackensack Meridian Health NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Hackensack Meridian Health NA
TERMINATED
(Mar 1, 2026)
PHASE2 Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Hackensack Meridian Health NA
COMPLETED
(Mar 1, 2026)
PHASE2 Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens Hackensack Meridian Health NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma Celgene NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Charite University, Berlin, Germany NA
RECRUITING
(Mar 1, 2026)
PHASE2 Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease Stichting European Myeloma Network NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Celgene NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Nemtabrutinib, Bortezomib, and Rituximab for WM Seoul National University Hospital NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 
